Nes-Ziona, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for patent application number 2020800620493. Once issued, the resulting patent will provide Enlivex with added intellectual property protection in China through at least 2040 with claims covering methods of using Allocetra ...

Core Insights - Portage Biotech has resumed patient enrollment in the final cohort of the dose escalation stage for PORT-6, a selective A2A antagonist, within its ADPORT-601 Phase 1b clinical trial, following a previous pause due to funding concerns [1][2] - The resumption of the trial indicates encouraging findings from earlier cohorts, reinforcing the company's confidence in the safety and therapeutic potential of PORT-6 [2][3] - The planned co-administration of PORT-6 and PORT-7, a selective A2B antagonist, aims to achieve a complete blockade of adenosine-induced immunosuppression in the tumor microenvironment, enhancing anti-tumor responses [3] Company Overview - Portage Biotech is a clinical-stage immuno-oncology company focused on advancing a pipeline of novel biologics to enhance the immune system's ability to combat cancer [4]

BioNTech SE (NASDAQ:BNTX) Q4 2024 Earnings Conference Call March 10, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder and Chief Executive Officer Ozlem Tureci - Co-Founder and Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Tazeen Ahmad - Bank of America Securities Terence Fl ...

Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Results Conference Call February 26, 2025 11:00 AM ET Company Participants Peter Vozzo - ICR Healthcare, IR Stacy Lindborg - President & Chief Executive Officer Douglas Faller - Chief Medical Officer David Gaiero - Interim Chief Financial Officer Michael Tardugno - Executive Chairman Khursheed Anwer - Chief Scientific Officer Conference Call Participants David Bautz - Zacks Small-Cap Research James Molloy - Alliance Global Partners Jason Kolbert - D. Boral Capital Kemp Dol ...

Imunon (IMNN) Q4 2024 Earnings Call February 27, 2025 11:00 AM ET Company Participants Peter Vozzo - Managing DirectorStacy Lindborg - President, CEO & DirectorDouglas Faller - Chief Medical OfficerDavid Gaiero - Chief Financial OfficerJoey Brusca - Equity Research AssociateKhursheed Anwer - Executive VP & Chief Scientific OfficerJason Kolbert - Managing Director Conference Call Participants David Bautz - Senior AnalystJames Molloy - Managing Director, Senior Biotechnology & Specialty Pharmaceuticals Equity ...

Incyte (INCY) Update / Briefing September 14, 2024 01:00 PM ET Speaker0 Greetings. Welcome to Incyte Investor Event at ESMO twenty twenty four. At this time, all participants are in a listen only mode. As a reminder, this conference is being recorded. I would now like to turn the conference over to Pablo Carreoni, Head of Research and Development. Thank you. You may begin. Speaker1 Thank you. Thank you everyone for coming. Thank you everyone who's joining us online for the webcast. We're very excited about ...

CG Oncology (CGON) Update / Briefing May 03, 2024 04:30 PM ET Speaker0 Welcome to the CG Oncology conference call to discuss updated results from the company's BOND-three Phase three clinical trial of Credo Stimogene for the treatment of high risk BCG unresponsive non muscle invasive bladder cancer. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a Q and A session. As a courtesy to others, we would ask participants to limit themselves to one qu ...